Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 14/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25404892 | 0.89 | PARG (0.50) | PARGUSP2HTTSMN1; SMN2 | |
| SCHEMBL26688687 | 0.88 | ALDH1A1 (0.53) | PARGUSP2HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL17825308 | 0.83 | PARG (0.52) | PARGHSD17B10 | |
| SCHEMBL17465680 | 0.81 | TP53 (0.50) | USP2ALDH1A1LMNA | |
| SCHEMBL15848086 | 0.81 | MAPT (0.61) | HTTSMN1; SMN2LMNA | |
| SCHEMBL25406371 | 0.81 | PARG (0.42) | PARGUSP2HTTSMN1; SMN2 | |
| SCHEMBL29602365 | 0.79 | CYP3A4 (0.52) | CYP3A4SMN1; SMN2ALDH1A1HSD17B10LMNA | |
| SCHEMBL13543494 | 0.79 | CYP3A4 (0.52) | CYP3A4SMN1; SMN2ALDH1A1HSD17B10LMNA | |
| SCHEMBL31736102 | 0.78 | USP2 (0.43) | PARGUSP2HTTSMN1; SMN2LMNA | |
| SCHEMBL15847752 | 0.77 | MAPT (0.62) | HTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023175185-A1 | 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | FORX THERAPEUTICS AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023175185-A1 | 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | FORX THERAPEUTICS AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023175184-A1 | 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | FORX THERAPEUTICS AG (CH) | 2023-09-21 | — | — | WO | disclosed |